Skip to main content

Remote Job Finders (RJF)

After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar

Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million raised to date, including a $45 million series A extension that closed Tuesday.

Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data

OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ulcerative colitis candidate lusvertikimab.

How North Carolina Attracted Amgen and Roche To Become a Next-Gen Obesity Drug Production Hotspot

Infrastructure and location have helped make Holly Springs a future hub for obesity drug production, with Amgen and Roche planning to manufacture GLP-1 therapies there to compete in the growing market.
Scroll to top